The randomized study by Semiglazov et al. (2011) [17] demonstrated that concurrent trastuzumab during NAC allowed approximately one-quarter of HER2-positive IBC/locally advanced breast cancer (LABC) patients to avoid mastectomy. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.